Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab).

NCT02658877 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02658877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab).
Lead sponsor
NYU Langone Health
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2016
Completion date
July 19, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma